Humacyte (NASDAQ:HUMA) Earns Buy Rating from Benchmark

Benchmark reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note published on Thursday morning, Benzinga reports. They currently have a $15.00 price objective on the stock.

Several other equities analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an overweight rating and set a $7.00 price target on shares of Humacyte in a research report on Tuesday, July 2nd. BTIG Research increased their target price on Humacyte from $8.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $8.60.

Humacyte Stock Down 3.8 %

Shares of NASDAQ HUMA opened at $5.27 on Thursday. The firm has a market cap of $627.57 million, a P/E ratio of -5.27 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The firm’s 50 day moving average price is $6.93 and its 200 day moving average price is $5.51.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, sell-side analysts anticipate that Humacyte will post -1.09 earnings per share for the current year.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 271,518 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the sale, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Brady W. Dougan sold 271,518 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the sale, the director now owns 4,559,140 shares of the company’s stock, valued at $33,281,722. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Dale A. Sander sold 39,389 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.68, for a total value of $263,118.52. Following the sale, the chief financial officer now owns 2,000 shares in the company, valued at $13,360. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,551,415 shares of company stock worth $10,508,440. 23.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. nVerses Capital LLC purchased a new position in Humacyte in the 2nd quarter valued at about $28,000. Victory Capital Management Inc. acquired a new stake in Humacyte during the 4th quarter valued at approximately $29,000. Kovitz Investment Group Partners LLC purchased a new stake in Humacyte during the 4th quarter worth approximately $35,000. China Universal Asset Management Co. Ltd. raised its position in shares of Humacyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after purchasing an additional 7,897 shares in the last quarter. Finally, Hartline Investment Corp purchased a new position in shares of Humacyte during the 1st quarter valued at approximately $70,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.